Monika Patel, Sakesh Kumar, Prachi Dugam, Aditya Singh and Prem N Yadav*,
{"title":"C-X-C基序趋化因子10/C-X-C基序趋化因子受体3信号传导诱导神经衰老和认知障碍","authors":"Monika Patel, Sakesh Kumar, Prachi Dugam, Aditya Singh and Prem N Yadav*, ","doi":"10.1021/acsptsci.5c00041","DOIUrl":null,"url":null,"abstract":"<p >Chemokine receptors belong to the G-protein-coupled receptor family, and emerging evidence suggests that chemokines are involved in central nervous system (CNS) aging. An increased level of CXCL10 in the CNS is reported in several neurodegenerative diseases, including Alzheimer’s disease and virus-associated dementia. We also observed significantly increased expression of CXCL10 and CXCR3 in the prefrontal cortex and hippocampus of aged C57BL/6J mice (12 and 18 month old mice). This leads us to hypothesize that CXCL10, being a component of the senescence-associated secretory phenotype, may aggravate/perpetuate the brain aging process and, finally, neurodegenerative diseases. To test this hypothesis, we administered CXCL10 (intracerebroventricular: ICV, 0.5 pg/h, 28 days) in 8-month-old C57BL/6J mice. We observed increased expression of senescent marker proteins p16<sup>INK4a</sup>, p21<sup>Cip1</sup>, and p53 and decreased expression of pRB in the prefrontal cortex, which was blocked by CXCR3-specific antagonist AMG487. Furthermore, chronic infusion of CXCL10 induced learning and memory deficits in the Y-maze, social recognition, contextual freeze tests, and c-FOS expression in the prefrontal cortex. To further determine the specificity of CXCL10/CXCR3 signaling, we treated the primary cortical neuron (days <i>in vitro</i>: DIV-7–8) with CXCL10 and found increased senescence in a CXCR3-dependent fashion. Using RFP-EGFP-LC3-tagged transgenic mice, we also demonstrated that CXCL10/CXCR3 signaling attenuates autophagy in primary cortical neurons. Lastly, using a c-FOS-iRFP reporter, we observed that increased CXCL10/CXCR3 signaling impairs glutamate signaling in primary cortical neurons. These results support the hypothesis that increased CXCL10/CXCR3 signaling in neurons exacerbates brain aging and could be targeted for the management of aging-associated CNS disorders.</p>","PeriodicalId":36426,"journal":{"name":"ACS Pharmacology and Translational Science","volume":"8 9","pages":"2908–2921"},"PeriodicalIF":3.7000,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"C-X-C Motif Chemokine 10/C-X-C Motif Chemokine Receptor 3 Signaling Induces Neural Senescence and Cognitive Impairments\",\"authors\":\"Monika Patel, Sakesh Kumar, Prachi Dugam, Aditya Singh and Prem N Yadav*, \",\"doi\":\"10.1021/acsptsci.5c00041\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >Chemokine receptors belong to the G-protein-coupled receptor family, and emerging evidence suggests that chemokines are involved in central nervous system (CNS) aging. An increased level of CXCL10 in the CNS is reported in several neurodegenerative diseases, including Alzheimer’s disease and virus-associated dementia. We also observed significantly increased expression of CXCL10 and CXCR3 in the prefrontal cortex and hippocampus of aged C57BL/6J mice (12 and 18 month old mice). This leads us to hypothesize that CXCL10, being a component of the senescence-associated secretory phenotype, may aggravate/perpetuate the brain aging process and, finally, neurodegenerative diseases. To test this hypothesis, we administered CXCL10 (intracerebroventricular: ICV, 0.5 pg/h, 28 days) in 8-month-old C57BL/6J mice. We observed increased expression of senescent marker proteins p16<sup>INK4a</sup>, p21<sup>Cip1</sup>, and p53 and decreased expression of pRB in the prefrontal cortex, which was blocked by CXCR3-specific antagonist AMG487. Furthermore, chronic infusion of CXCL10 induced learning and memory deficits in the Y-maze, social recognition, contextual freeze tests, and c-FOS expression in the prefrontal cortex. To further determine the specificity of CXCL10/CXCR3 signaling, we treated the primary cortical neuron (days <i>in vitro</i>: DIV-7–8) with CXCL10 and found increased senescence in a CXCR3-dependent fashion. Using RFP-EGFP-LC3-tagged transgenic mice, we also demonstrated that CXCL10/CXCR3 signaling attenuates autophagy in primary cortical neurons. Lastly, using a c-FOS-iRFP reporter, we observed that increased CXCL10/CXCR3 signaling impairs glutamate signaling in primary cortical neurons. These results support the hypothesis that increased CXCL10/CXCR3 signaling in neurons exacerbates brain aging and could be targeted for the management of aging-associated CNS disorders.</p>\",\"PeriodicalId\":36426,\"journal\":{\"name\":\"ACS Pharmacology and Translational Science\",\"volume\":\"8 9\",\"pages\":\"2908–2921\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-09-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Pharmacology and Translational Science\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acsptsci.5c00041\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Pharmacology and Translational Science","FirstCategoryId":"1085","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsptsci.5c00041","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Chemokine receptors belong to the G-protein-coupled receptor family, and emerging evidence suggests that chemokines are involved in central nervous system (CNS) aging. An increased level of CXCL10 in the CNS is reported in several neurodegenerative diseases, including Alzheimer’s disease and virus-associated dementia. We also observed significantly increased expression of CXCL10 and CXCR3 in the prefrontal cortex and hippocampus of aged C57BL/6J mice (12 and 18 month old mice). This leads us to hypothesize that CXCL10, being a component of the senescence-associated secretory phenotype, may aggravate/perpetuate the brain aging process and, finally, neurodegenerative diseases. To test this hypothesis, we administered CXCL10 (intracerebroventricular: ICV, 0.5 pg/h, 28 days) in 8-month-old C57BL/6J mice. We observed increased expression of senescent marker proteins p16INK4a, p21Cip1, and p53 and decreased expression of pRB in the prefrontal cortex, which was blocked by CXCR3-specific antagonist AMG487. Furthermore, chronic infusion of CXCL10 induced learning and memory deficits in the Y-maze, social recognition, contextual freeze tests, and c-FOS expression in the prefrontal cortex. To further determine the specificity of CXCL10/CXCR3 signaling, we treated the primary cortical neuron (days in vitro: DIV-7–8) with CXCL10 and found increased senescence in a CXCR3-dependent fashion. Using RFP-EGFP-LC3-tagged transgenic mice, we also demonstrated that CXCL10/CXCR3 signaling attenuates autophagy in primary cortical neurons. Lastly, using a c-FOS-iRFP reporter, we observed that increased CXCL10/CXCR3 signaling impairs glutamate signaling in primary cortical neurons. These results support the hypothesis that increased CXCL10/CXCR3 signaling in neurons exacerbates brain aging and could be targeted for the management of aging-associated CNS disorders.
期刊介绍:
ACS Pharmacology & Translational Science publishes high quality, innovative, and impactful research across the broad spectrum of biological sciences, covering basic and molecular sciences through to translational preclinical studies. Clinical studies that address novel mechanisms of action, and methodological papers that provide innovation, and advance translation, will also be considered. We give priority to studies that fully integrate basic pharmacological and/or biochemical findings into physiological processes that have translational potential in a broad range of biomedical disciplines. Therefore, studies that employ a complementary blend of in vitro and in vivo systems are of particular interest to the journal. Nonetheless, all innovative and impactful research that has an articulated translational relevance will be considered.
ACS Pharmacology & Translational Science does not publish research on biological extracts that have unknown concentration or unknown chemical composition.
Authors are encouraged to use the pre-submission inquiry mechanism to ensure relevance and appropriateness of research.